Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 5/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | OTC | P00480 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphonic Acid SCHEMBL8850015 | 0.98 | LMNA (0.39) | LMNABLMCYP3A4NFKB1PMP22 | |
| Phosphonic Acid SCHEMBL6861643 | 0.98 | LMNA (0.39) | LMNABLMCYP3A4NFKB1PMP22 | |
| Phosphonic Acid SCHEMBL11037740 | 0.98 | LMNA (0.39) | LMNABLMCYP3A4NFKB1PMP22 | |
| Phosphonic Acid SCHEMBL5718113 | 0.96 | LMNA (0.38) | LMNABLMCYP3A4NFKB1PMP22 | |
| SCHEMBL302911 | 0.91 | — | — | |
| Phosphonic Acid SCHEMBL7622219 | 0.87 | LMNA (0.43) | LMNABLMCYP3A4NFKB1PMP22 | |
| Phosphonic Acid SCHEMBL7049850 | 0.84 | LMNA (0.40) | LMNABLMCYP3A4NFKB1PMP22 | |
| Phosphonic Acid SCHEMBL10776655 | 0.82 | LMNA (0.39) | LMNABLMCYP3A4NFKB1PMP22 | |
| Phosphonic Acid SCHEMBL9193304 | 0.79 | ANPEP (0.40) | GABBR2GABBR1ALDH1A1ANPEPERAP2 | |
| Phosphonic Acid SCHEMBL10946315 | 0.77 | ALDH1A1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0983060-A4 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2002-04-24 | — | — | EP | claimed |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX THERAPEUTICS, INC. | 2002-04-04 | — | — | US | claimed |
| EP-0983060-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998051282-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 1998-11-19 | — | — | WO | claimed |
| EP-0421921-B1 | Double coated granules | CIBA GEIGY AG (CH) | 1994-04-27 | — | — | EP | claimed |
| EP-0177443-B1 | CRYSTAL MODIFICATION OF DISODIUM-3-AMINO-1-HYDROXY-PROPANE-1,1-DIPHOSPHONATE | CIBA-GEIGY AG (CH) | 1989-10-18 | — | — | EP | claimed |
| US-20040091541-A1 | Solid matrix therapeutic compositions | UNGER EVAN C (US) | 2004-05-13 | — | — | US | disclosed |
| EP-0797443-B1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIO-AVAILABILITY OF INOSITOL PHOSPHATE | BIONERIS AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| US-6534674-B2 | Prepared by neutralizing pamidronic acid with sodium compound, drying disodium pamidronate, dissolving in water, filtering sparingly soluble materials, allowing the filtrate to crystallize | HANLIM PHARM. CO., LTD. (KR) | 2003-03-18 | — | — | US | disclosed |
| EP-0983060-A4 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX THERAPEUTICS, INC. | 2002-04-04 | — | — | US | disclosed |
| US-20010018072-A1 | Solid matrix therapeutic compositions | IMARX THERAPEUTICS, INC. | 2001-08-30 | — | — | US | disclosed |
| EP-0983060-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | IMARX PHARMACEUTICAL CORP. (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0444038-A1 | CONJUGATES FOR BONE IMAGING AND BONE CANCER THERAPY. | NEORX CORP (US) | 1991-09-04 | — | — | EP | disclosed |
| US-4983385-A | For wet body surface, water-soluble polymer hydrogel, methacrylate copolymer, solubilizer | SUNSTAR KABUSHIKI KAISHA (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4711880-A | FOR CALCIUM AND PHOSPHATE METABOLISM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1987-12-08 | — | — | US | disclosed |
| US-4639338-A | Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate | CIBA-GEIGY CORPORATION (US) | 1987-01-27 | — | — | US | disclosed |
| US-4578376-A | 6-AMINO-1-HYDROXYHEXANE-1,1-DIPHOSPHONIC ACID; PAGET'S DOSEASE | ISTITUTO GENTILI S.P.A. (IT) | 1986-03-25 | — | — | US | disclosed |
| US-4446052-A | Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate | THE PROCTER & GAMBLE COMPANY (US) | 1984-05-01 | — | — | US | disclosed |
| EP-0094714-A2 | Gel-like calcium salt of 1-hydroxy-3-aminopropane-1,1-diphosphonic acid | THE PROCTER & GAMBLE COMPANY (US) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091541-A1 | Solid matrix therapeutic compositions | MMP7, MMP1, MMP17 | LMNA 1828/4885BLM 907/4885CYP3A4 4751/4885 |
| US-20020039594-A1 | SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME | EXOSC9, EXOSC5, EXOSC4 | LMNA 3245/4885BLM 629/4885CYP3A4 2363/4885 |
| US-20010018072-A1 | Solid matrix therapeutic compositions | MMP7, MMP1, MMP17 | LMNA 1828/4885BLM 907/4885CYP3A4 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.